Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more

Recent & Breaking News (NDAQ:LEXX)

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

TheNewsWire 10 days ago

Lexaria Awarded New Patents

TheNewsWire April 2, 2024

Lexaria to Present at The LD Micro Invitational XIV

Newsfile March 21, 2024

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

TheNewsWire March 14, 2024

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

TheNewsWire March 7, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

TheNewsWire March 5, 2024

7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study

TheNewsWire March 4, 2024

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

TheNewsWire March 1, 2024

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TheNewsWire February 16, 2024

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Accesswire February 15, 2024

Lexaria Submits Investigational New Drug Application

TheNewsWire January 30, 2024

Lexaria's Submits Investigational New Drug Application

Accesswire January 30, 2024

Lexaria Releases Annual Letter from the CEO

TheNewsWire January 24, 2024

Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program

TheNewsWire January 16, 2024

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

GlobeNewswire January 11, 2024

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

GlobeNewswire January 9, 2024

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus-Branded GLP-1 drug Semaglutide

TheNewsWire January 4, 2024

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide

Accesswire January 4, 2024

Lexaria's Investigational New Drug Application Filing Update

TheNewsWire December 7, 2023

Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study

TheNewsWire November 28, 2023